NCT06642792View on ClinicalTrials.gov

A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

February 29, 2028

Conditions
Classic Hodgkin Lymphoma
Interventions
DRUG

AK129

Subjects receive AK129 intravenously.

DRUG

AK117

Subjects receive AK117 intravenously.

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY